Categories: News

HEXO Acknowledges Zenabis Group CCAA Filing

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021.

GATINEAU, Quebec, June 17, 2022 (GLOBE NEWSWIRE) — HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) (“HEXO” or the “Company”) acknowledged today that its wholly-owned subsidiary, Zenabis Global Inc. (“Zenabis”), as well as Zenabis’ direct and indirect wholly-owned subsidiaries (collectively, the “Zenabis Group”), have filed a petition with the Superior Court of Québec for protection under the Companies’ Creditors Arrangement Act (“CCAA”) in order to restructure their business and financial affairs. HEXO understands that Ernst & Young Inc. has been appointed as the Monitor to oversee the CCAA proceedings.

The CCAA petition is limited to the Zenabis Group and neither HEXO Corp. nor any of its subsidiaries, other than the members of the Zenabis Group, are petitioners or parties to the CCAA Proceedings.

About HEXO

HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, Redecan, UP Cannabis, Namaste Original Stash, 48North, Trail Mix, Bake Sale, REUP and Latitude brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss CBD USA, a joint venture with Molson-Coors. With the completion of HEXO’s recent acquisitions of Redecan and 48North, HEXO is a leading cannabis products company in Canada by recreational market share. For more information, please visit hexocorp.com.

For further information, please contact:
Investor Relations:
invest@hexo.com
www.hexocorp.com 

For media inquiries please contact:
media@hexo.com

For further information regarding the Zenabis Group’s CCAA proceedings, please contact:
Ernst & Young Inc.
900 Boul. de Maisonneuve O., Bureau 2300
Montréal, Québec, H3A 0A8
zenabis.monitor@ca.ey.com
1-855-941-7757

 

Staff

Recent Posts

WELL Health Announces Receipt of MCTO

VANCOUVER, BC, April 1, 2025 /PRNewswire/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF)…

41 minutes ago

Announcing Helient Technologies

Helient Technologies, LLC launches to deliver scalable cloud and hybrid technology solutions. HADDONFIELD, N.J., April…

41 minutes ago

Rapid Dose Therapeutics Corp. Announces Payment in Shares for Quarterly Interest on Secured Debt and Update on Shares for Debt Settlement with Creditors

Burlington, Ontario--(Newsfile Corp. - April 1, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"…

3 hours ago

Beyond Medical Technologies Announces Private Placement to Advance Blockchain Infrastructure

Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…

5 hours ago

TE Connectivity completes acquisition of Richards Manufacturing

GALWAY, Ireland, April 1, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL), a world leader…

7 hours ago

Koning Health Announces Expansion of Vera Scan Installations Across the United States

NORCROSS, Ga., April 1, 2025 /PRNewswire/ -- Koning Health proudly announces its continued nationwide expansion,…

7 hours ago